Refractory Angina Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

Refractory Angina Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

“”Refractory Angina – Market Insights, Epidemiology, and Market Forecast-2030″”

 

DelveInsight has launched a report on “Refractory Angina – Market Insights, Epidemiology, and Market Forecast-2030

DelveInsight’s “ Refractory Angina – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Refractory Angina, historical and forecasted epidemiology as well as the Refractory Angina market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the Facts:

  1. The total prevalent cases of Refractory Angina in 7 major markets ranges from 29,17,196 in 2017.
  2. The United States accounted for most prevalent cases of RA in 7MM with 19,05,602 cases in 2017.
  3. Germany accounted for most number of prevalent cases of RA with 5,13,896 cases in 2017.
  4. Japan accounted for 27,432 cases in 2017 which are expected to grow during the study period (2017–2030).

 

Key facts of the report:

1. Refractory Angina market report covers a descriptive overview and comprehensive insight of the Refractory Angina epidemiology and Refractory Angina market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. Refractory Angina market report provides insights on the current and emerging therapies. 

3. Refractory Angina market report offers a global historical and forecasted market covering drug outreach in 7MM.

4. Refractory Angina market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Refractory Angina market.

 

Request for Sample Pages:  https://www.delveinsight.com/sample-request/refractory-angina-market

 

“According the DelveInsight, higher Prevalence of Refractory Angina is observed among males as compared to females in 7MM.”

 

Refractory Angina (RA) is a chronic condition where pain remain persistent for the duration of less than or equal to 3 months, characterized by angina. Angina is a type of chest pain caused by reduced blood flow to the heart. Angina has two types, chronic or stable angina and unstable angina. Around 10–15% of patients of Chronic Angina meet the measures of RA. The clinical load of RA is growing rapidly due to an ageing population and improved Coronary Artery Disease (CAD). 

Symptoms of RA are chest pain, shortness of breath, and easy fatigability. RA also shows neurological, psychogenic and mitochondrial dysfunctions in addition to tissue ischemia which are responsible for an insistent cardiac pain. These symptoms causes poor self-perceived health status, high incidence of depression, and burden to the health care system due to significant resource utilization.

Patients with RA are a heterogeneous group that remain significantly limited by persistent debilitating chest discomfort despite optimal conventional therapy.

 

“RA is classified on the basis of grading the pain. Among these sub-types, Class III contributes the major patient share of RA followed by Class IV angina.”

 

Some of the key companies working on Refractory Angina are:

  • Imbria Pharmaceuticals
  • Caladrius Biosciences, Inc.
  • Generx: Angionetics Inc.
  • XyloCor Therapeutics, Inc.

And Many Others.

The launch of the emerging therapies is expected to significantly impact the Refractory Angina treatment scenario in the upcoming years:-

 Drugs Covered:

  • IMB-101
  • Auto CD34+ Cells
  • Generx
  • XC001

And Many Others.

 

Request a Free Sample Report @ https://www.delveinsight.com/sample-request/refractory-angina-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Refractory Angina

3. Competitive Intelligence Analysis for Refractory Angina

4. Refractory Angina: Market Overview at a Glance

4.1. Refractory Angina Total Market Share (%) Distribution in 2017

4.2. Refractory Angina Total Market Share (%) Distribution in 2030

5. Refractory Angina: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Refractory Angina Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Refractory Angina Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Refractory Angina Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Refractory Angina Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Refractory Angina Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Refractory Angina Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Refractory Angina Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Refractory Angina Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Refractory Angina Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Refractory Angina Treatment and Management

8.2. Refractory Angina Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Refractory Angina Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Refractory Angina: Seven Major Market Analysis

13.1. Key Findings

13.2. Refractory Angina Market Size in 7MM

13.3. Refractory Angina Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Refractory Angina Total Market Size in the United States

15.1.2. Refractory Angina Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Refractory Angina Total Market Size in Germany

15.3.2. Refractory Angina Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Refractory Angina Total Market Size in France

15.4.2. Refractory Angina Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Refractory Angina Total Market Size in Italy

15.5.2. Refractory Angina Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Refractory Angina Total Market Size in Spain

15.6.2. Refractory Angina Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Refractory Angina Total Market Size in the United Kingdom

15.7.2. Refractory Angina Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Refractory Angina Total Market Size in Japan

15.8.3. Refractory Angina Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Refractory Angina

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Related Reports:

Refractory Angina – Pipeline Insights, 2020

The Refractory Angina report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Refractory Angina across the complete product development cycle, including all clinical and nonclinical stages.

Refractory Angina – Epidemiology Forecast to 2030

The Refractory Angina epidemiology covered in the report provides historical as well as forecasted Refractory Angina epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/